- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03562052
Lung Cancer Screening in a Population Exposed to Occupational Lung Carcinogens (LUCSO)
LUng Cancer Screening With Low-dose Computed Tomography in a Population Exposed to Occupational Lung Carcinogens
The good clinical practice guidelines for the surveillance of workers after occupational exposure to lung carcinogens were approved by the Haute Autorité de la Santé (French National Authority for Health) and the Institut National du Cancer (French National Cancer Institute) in December 2015 and one recommendation of these guidelines concerns the setting-up of a trial of low-dose chest computed tomography (CT) lung cancer screening in subjects occupationally exposed to lung carcinogens at high-risk of lung cancer (Expert consensus).
In LUCSO study, the investigators propose to conduct, under strictly defined conditions, a feasibility study of lung cancer screening in a population defined as being at high risk of lung cancer according to these good clinical practice guidelines. This population consists of smokers, aged from 55 to 74 years, currently or previously exposed to International Agency for Research on Cancer lung group 1 lung carcinogens.
The primary objective of this study is to evaluate the complex organization of lung cancer screening in the target population. This evaluation will focus on the following indicators:
- Screening activity indicator: screening coverage rate over two years
- Test quality indicator: validity of self-administered questionnaires to target the high-risk population
- Examination quality indicator: lung cancer detection rate, lung cancer detection rates by stage, validity of low-dose chest CT scan
- Follow-up indicator: smoking cessation rate, mortality rate This trial will be conducted in 8 French departments, by six reference centers specialized in occupational health (SRC).
In view of the exploratory nature of this trial, it is proposed to initially test the feasibility and acceptability of lung cancer screening sequentially over the first two years (Phase 1: 2021-2023, 24 months) in only two SRC (Val-de-Marne and Gironde).
The trial will be conducted in several steps:
- Identification of subjects currently or previously occupationally exposed to lung carcinogens by a screening invitation letter sent by Departmental Cancer Screening Centers to subjects aged from 55 to 74 years.
- Evaluation of occupational exposure to lung carcinogens
- Evaluation of the lung cancer risk level and verification of eligibility
- Screening procedure: Chest CT scans will be performed by centers specialized in chest imaging
- Lung cancer follow-up when an abnormality suggestive of lung cancer is demonstrated.
Study Overview
Status
Conditions
Detailed Description
The good clinical practice guidelines for the surveillance of workers after occupational exposure to lung carcinogens were approved by the Haute Autorité de la Santé (French National Authority for Health) and the Institut National du Cancer (French National Cancer Institute) in December 2015 and the Recommendation R12 of these guidelines concerns the setting-up of a trial of low-dose chest computed tomography (CT) lung cancer screening in subjects occupationally exposed to lung carcinogens at high-risk of lung cancer (Expert consensus).
In LUCSO study, the investigators propose to conduct, under strictly defined conditions, a feasibility study of lung cancer screening in a population defined as being at high risk of lung cancer according to these good clinical practice guidelines. This population consists of smokers, aged from 55 to 74 years, currently or previously exposed to International Agency for Research on Cancer lung group 1 lung carcinogens.
The primary objective of this study is to evaluate the organization of lung cancer screening in the target population. This evaluation will focus on the following indicators:
- Screening activity indicator: screening coverage rate over two years
- Test quality indicator: validity of self-administered questionnaires to target the high-risk population
- Examination quality indicator: lung cancer detection rate, lung cancer detection rates by stage, validity of low-dose chest CT scan
- Follow-up indicator: smoking cessation rate, mortality rate
The secondary objectives of the study are:
- Describe the population recruited in each step of the protocol
- Develop a tool to identify subjects exposed to pulmonary carcinogens and with high-risk of lung cancer
- Evaluate the impact of the proposed screening programme on smoking cessation at one, two and three years.
- Evaluate the social impact of the screening campaign
- Conduct a cost-effectiveness analysis of the programme
The proposed study will take place in multidisciplinary and specialized reference centers (SRC) in various French districts participating in the programme, to welcome patients participating. It is organized into six workpackages (WP):
- WP1: Methodology - Epidemiology
- WP2: Evaluation of occupational exposure
- WP3: Imaging
- WP4: Lung cancer follow-up strategy
- WP5: Smoking cessation
- WP6: Medico-economic analysis Six specialized reference centers are proposed in four different regions in order to test a potential region effect and to allow the recruitment by each SRC of about 200 to 600 new eligible subjects per year and per department according to the population and the age pyramid of each department
- SRC1: Centre Intercommunal de Créteil for the Val-de-Marne (94), Seine-et-Marne (77), and Essonne (91) departments
- SRC2: Bordeaux University Hospital for the Gironde (33) department
- SRC3: Rennes University Hospital for the Ille-et-Vilaine (35) department
- SRC4: Brest University Hospital for the Finistère (29) department
- SRC5: Caen University Hospital for the Calvados (14) department
- SRC6: Rouen University Hospital for the Seine-Maritime (76) department
Each of these centers is voluntary and possesses the four essential prerequisites: an occupational health clinic - radiology team with specific skills in chest imaging - pulmonology team or network of pulmonologists specialized in lung cancer - smoking cessation team.
In view of the complexity of this organization, it is proposed to initially test the feasibility and acceptability of the screening programme sequentially for the first two years (24 months) in two SRCs (SRC1 and SRC2): "Phase 1: 2021-2023". It is expected to extend the study to the other SRCs after two years: "Phase 2: 2023-2029". Ad hoc adjustments will be decided for the creation of SRCs in the third year on the basis of the data acquired in the two pilot departments, especially on the expected target population participation rate. Mortality will be monitored at least until 2031.
The trial will be conducted in several steps:
- Identification of subjects currently or previously occupationally exposed to lung carcinogens by a screening invitation letter sent by Departmental Cancer Screening Centers to subjects aged from 55 to 74 years.
- Evaluation of occupational exposure to lung carcinogens
- Evaluation of the lung cancer risk level and verification of eligibility
- Screening procedure: Chest CT scans will be performed by centers specialized in chest imaging
- Lung cancer follow-up when an abnormality suggestive of lung cancer is demonstrated.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
-
Bordeaux, France, 33076
- Recruiting
- Centre Hospitalier Universitaire de Bordeaux
-
Bordeaux, France, 33076
- Active, not recruiting
- Universite de Bordeaux
-
Brest, France, 29609
- Not yet recruiting
- Centre Hospitalier Universitaire de Brest
-
Contact:
- David LUCAS, Dr
-
Caen, France, 14033
- Not yet recruiting
- Centre Hospitalier Universitaire de Caen
-
Créteil, France, 94010
- Recruiting
- Centre Hospitalier Intercommunal de Créteil
-
Rennes, France, 35033
- Not yet recruiting
- Centre Hospitalier Universitaire de Rennes
-
Rouen, France, 76032
- Not yet recruiting
- Centre Hospitalier Universitaire de Rouen
-
Toulon, France, 83000
- Not yet recruiting
- Hôpital d'Instruction des Armées Sainte-Anne
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
Subjects at high risk of lung cancer: current smokers smoking 30 pack-years or more or ex-smokers smoking 30 pack-years or more and who have quit smoking for less than 15 years and currently or previously occupationally exposed to lung carcinogens. With an algorithm for determination of minimal duration of exposure to occupational carcinogens (according to the type and duration of occupational lung carcinogens)
Exclusion Criteria:
- Presence of clinical signs of lung cancer
- Subjects with a history of lung cancer
- Presence of serious short-term life-threatening comorbidities
- Absence of occupational exposure to lung carcinogens according to the predefined criteria
- Subjects already included in another prospective cohort study
- Subjects already assessed by chest CT scan during the previous year
- No tobacco exposure or insufficient tobacco exposure or smoking cessation for more than 15 years.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of detected lung cancer
Time Frame: Year 1
|
The proportion of subjects with lung cancer detected among the subjects performing the low-dose chest CT scan
|
Year 1
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of detected lung cancer
Time Frame: Year 2
|
The proportion of subjects with lung cancer detected among the subjects performing the low-dose chest CT scan
|
Year 2
|
Rate of detected lung cancer
Time Frame: Day 0
|
The proportion of subjects with lung cancer detected among the subjects performing the low-dose chest CT scan
|
Day 0
|
Participation rate
Time Frame: Day 0
|
The proportion of subjects performing the low-dose chest CT scan among eligible responders during the first phase of the study
|
Day 0
|
Rate of detected lung cancer in subjects exposed to occupational carcinogens
Time Frame: Day 0
|
The proportion of subjects with lung cancer detected among the subjects exposed to occupational carcinogens and performing the low-dose chest CT scan
|
Day 0
|
Rate of detected lung cancer in subjects exposed to occupational carcinogens
Time Frame: Year 1
|
The proportion of subjects with lung cancer detected among the subjects exposed to occupational carcinogens and performing the low-dose chest CT scan
|
Year 1
|
Rate of detected lung cancer in subjects exposed to occupational carcinogens
Time Frame: Year 2
|
The proportion of subjects with lung cancer detected among the subjects exposed to occupational carcinogens and performing the low-dose chest CT scan
|
Year 2
|
Stage of detected lung cancers
Time Frame: Day 0
|
Day 0
|
|
Stage of detected lung cancers
Time Frame: Year 1
|
Year 1
|
|
Stage of detected lung cancers
Time Frame: Year 2
|
Year 2
|
|
Smoking cessation rate obtained in smokers in the sreened population
Time Frame: Year 3
|
The proportion of subjects with smoking cessation among smokers
|
Year 3
|
Mortality rate in the sreened population
Time Frame: Year 3
|
Year 3
|
|
Mortality rate in the sreened population
Time Frame: Year 5
|
Year 5
|
|
Mortality rate in the sreened population
Time Frame: Year 7
|
Year 7
|
|
Mortality rate in the non-screened population
Time Frame: Year 3
|
Year 3
|
|
Mortality rate in the non-screened population
Time Frame: Year 5
|
Year 5
|
|
Lung cancer rate in non-screened subjects but met at the Occupational Disease Consultation Center
Time Frame: Year 3
|
Year 3
|
|
Mortality rate in the non-screened population
Time Frame: Year 7
|
Year 7
|
|
Lung cancer rate in non-screened subjects but met at the Occupational Disease Consultation Center
Time Frame: Year 5
|
Year 5
|
|
Lung cancer rate in non-screened subjects but met at the Occupational Disease Consultation Center
Time Frame: Year 7
|
Year 7
|
|
Rate of detected lung cancer and stage of detected lung cancer in the non-screened population
Time Frame: Year 3
|
Year 3
|
|
Rate of detected lung cancer and stage of detected lung cancer in the non-screened population
Time Frame: Year 5
|
Year 5
|
|
Rate of detected lung cancer and stage of detected lung cancer in the non-screened population
Time Frame: Year 7
|
Year 7
|
|
Percentage of subjects participating in all screening (over the three years)
Time Frame: Year 3
|
Year 3
|
|
Percentage of subjects participating in all screening (over the three years)
Time Frame: Year 4
|
Year 4
|
|
Percentage of the subjects lost during follow-up in the screened population (follow-up at one year, two years, completion of other complementary exams)
Time Frame: Year 1
|
Year 1
|
|
Percentage of the subjects lost during follow-up in the screened population (follow-up at one year, two years, completion of other complementary exams)
Time Frame: Year 2
|
Year 2
|
|
Validity of the detailed personalised self-administered questionnaire for the evaluation of occupational exposures
Time Frame: Day 0
|
Day 0
|
|
Number of cases recognized as occupational disease (for lung cancer or other occupational diseases)
Time Frame: Year 2
|
Year 2
|
|
Proportion of invasive diagnostic procedures
Time Frame: Day 0
|
Day 0
|
|
Proportion of invasive diagnostic procedures
Time Frame: Year 1
|
Year 1
|
|
Proportion of invasive diagnostic procedures
Time Frame: Year 2
|
Year 2
|
|
Proportion of non-invasive diagnostic procedures
Time Frame: Day 0
|
Day 0
|
|
Proportion of non-invasive diagnostic procedures
Time Frame: Year 1
|
Year 1
|
|
Proportion of non-invasive diagnostic procedures
Time Frame: Year 2
|
Year 2
|
|
Proportion of serious and non-serious adverse events related to screening
Time Frame: Day 0
|
Day 0
|
|
Proportion of serious and non-serious adverse events related to screening
Time Frame: Year 1
|
Year 1
|
|
Proportion of serious and non-serious adverse events related to screening
Time Frame: Year 2
|
Year 2
|
|
Proportion of subjects stopping smoking at each stage of screening
Time Frame: Day 0
|
Day 0
|
|
Proportion of subjects stopping smoking at each stage of screening
Time Frame: Year 1
|
Year 1
|
|
Proportion of subjects stopping smoking at each stage of screening
Time Frame: Year 2
|
Year 2
|
|
The time period between each step of the screening (evaluation of the exposure, addressing in consultation of occupational diseases, inclusion, different exams of the follow-up)
Time Frame: Day 0
|
Day 0
|
|
The time period between each step of the screening (evaluation of the exposure, addressing in consultation of occupational diseases, inclusion, different exams of the follow-up)
Time Frame: Year 1
|
Year 1
|
|
The time period between each step of the screening (evaluation of the exposure, addressing in consultation of occupational diseases, inclusion, different exams of the follow-up)
Time Frame: Year 3
|
Year 3
|
|
Number of additional radiological examinations performed besides the prescribed CT scans of the protocol
Time Frame: Subject inclusion
|
Subject inclusion
|
|
Number of additional radiological examinations performed besides the prescribed CT scans of the protocol
Time Frame: Year 1
|
Year 1
|
|
Number of additional radiological examinations performed besides the prescribed CT scans of the protocol
Time Frame: Year 2
|
Year 2
|
|
Number of additional radiological examinations performed besides the prescribed CT scans of the protocol
Time Frame: Year 3
|
Year 3
|
|
Number of additional radiological examinations performed besides the prescribed CT scans of the protocol
Time Frame: Year 4
|
Year 4
|
|
Number of additional radiological examinations performed besides the prescribed CT scans of the protocol
Time Frame: Year 5
|
Year 5
|
|
Number of hospitalizations
Time Frame: Subject inclusion
|
Subject inclusion
|
|
Number of hospitalizations
Time Frame: Year 1
|
Year 1
|
|
Number of hospitalizations
Time Frame: Year 2
|
Year 2
|
|
Number of hospitalizations
Time Frame: Year 3
|
Year 3
|
|
Number of hospitalizations
Time Frame: Year 4
|
Year 4
|
|
Number of hospitalizations
Time Frame: Year 5
|
Year 5
|
|
Number of lung surgery
Time Frame: Subject inclusion
|
Subject inclusion
|
|
Number of lung surgery
Time Frame: Year 1
|
Year 1
|
|
Number of lung surgery
Time Frame: Year 2
|
Year 2
|
|
Number of lung surgery
Time Frame: Year 3
|
Year 3
|
|
Number of lung surgery
Time Frame: Year 4
|
Year 4
|
|
Number of lung surgery
Time Frame: Year 5
|
Year 5
|
|
Number of chemotherapy
Time Frame: Day 0
|
Day 0
|
|
Number of chemotherapy
Time Frame: Year 1
|
Year 1
|
|
Number of chemotherapy
Time Frame: Year 2
|
Year 2
|
|
Number of chemotherapy
Time Frame: Year 3
|
Year 3
|
|
Number of chemotherapy
Time Frame: Year 4
|
Year 4
|
|
Number of chemotherapy
Time Frame: Year 5
|
Year 5
|
Collaborators and Investigators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- LUCSO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lung Cancer
-
M.D. Anderson Cancer CenterRecruitingStage III Lung Cancer AJCC v8 | Lung Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage... and other conditionsUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)RecruitingStage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage IA3 Lung Cancer AJCC v8 | Stage IB Lung Cancer...United States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage I Lung Cancer... and other conditionsUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingCaregiver | Stage III Lung Cancer AJCC v7 | Stage I Lung Cancer AJCC v7 | Stage II Lung Cancer AJCC v7 | Stage IB Lung Cancer AJCC v7 | Stage IA Lung Cancer AJCC v7 | Stage IIA Lung Cancer AJCC v7 | Stage IIB Lung Cancer AJCC v7 | Stage IIIA Lung Cancer AJCC v7 | Stage IIIB Lung Cancer AJCC v7United States
-
Dana-Farber Cancer InstituteMedWaves, IncNot yet recruitingLung Cancer | Lung Cancer Stage I | Lung Cancer Stage II | Stage I Lung Cancer | Stage I - II Primary Lung Cancer | Stage II Lung CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI); Genentech, Inc.RecruitingStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Lung Non-Small Cell Carcinoma | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung... and other conditionsUnited States
-
WindMIL TherapeuticsBristol-Myers SquibbTerminatedNSCLC | Lung Cancer | Lung Cancer Metastatic | Lung Cancer, Non-small Cell | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer MetastaticUnited States
-
Emory UniversityNational Cancer Institute (NCI)TerminatedLung Non-Small Cell Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage IA3 Lung Cancer AJCC v8 | Stage IB Lung Cancer...United States
-
University of California, San FranciscoMerck Sharp & Dohme LLCWithdrawnLung Non-Small Cell Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage IA3 Lung Cancer AJCC v8 | Stage IB Lung Cancer...United States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Metastatic Lung Carcinoma | Stage IV Lung Cancer AJCC v8 | Head and Neck Carcinoma | Lung Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung... and other conditionsUnited States